Agios Pharmaceuticals initiated with an Overweight at Piper Jaffray. Piper Jaffray analyst Tyler Van Buren started Agios Pharmaceuticals with an Overweight rating and $125 price target. The analyst believes both Idhifa and Tibsovo will experience commercial success while AG-348 for pyruvate kinase deficiency could represent a $750M-plus opportunity. He sees “no shortage of potential opportunities for future value creation.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.